Integration of pharmacoinformatics as part of onco-culture: predicting chemotherapy-induced nausea and vomiting from patients' anxiety symptoms
Yap, Kevin Yi-Lwern, Low, Xiu Hui and Chan, Alexandre. (2011) Integration of pharmacoinformatics as part of onco-culture: predicting chemotherapy-induced nausea and vomiting from patients' anxiety symptoms. Supportive Care In Cancer, Vol.19 (Suppl.2). S115-S116. ISSN 0941-4355Full text not available from this repository.
Official URL: http://dx.doi.org/10.1007/s00520-011-1184-y
Objectives: Patients with and without CINV report different anxiety symptoms. This study utilized a novel pharmacoinformatics approach to identify anxiety symptoms that could predict chemotherapy-induced nausea and vomiting (CINV) based on a 21-item objective assessment tool (Beck Anxiety Inventory). Methods: Asian patients on a variety of chemotherapy regimens and appropriate antiemetic treatment were recruited from January 2007–July 2010. CINV events were recorded in a CINV diary. The principal variable (PV) approach was used for pharmacoinformatic analysis of 21 anxiety symptoms to differentiate patients with and without complete response (CR), complete protection (CP) and complete control (CC). Results: 710 patients were recruited. Mean age was 52.9±10.3 years. Majority were females (67%) and Chinese (84%). Patient proportions that achieved CR, CP and CC were 58%, 42% and 27% respectively. Seven items (33%) were identified as clinical predictors of the CINV endpoints. ‘Fear of dying’ was a predictor for CINV in head-and-neck and gastrointestinal cancer patients receiving platinum-based chemotherapies. In addition, ‘hot/cold sweats’ was associated with head-and-neck cancer patients, while ‘nervousness’ and ‘faintness’ were mainly observed in gastrointestinal cancer patients. On the other hand, ‘fear of the worst’, ‘numbness’ and ‘unable to relax’ predicted for poor CINV control in breast cancer patients receiving anthracycline-based chemotherapies. Conclusions: This study has successfully demonstrated that anxiety symptoms vary among patients who experience different cancers. They may experience different efficacy outcomes with their antiemetics. The PV approach is able to identify 7 anxiety-associated symptoms that can be clinically-relevant when assessing CINV risks among cancer patients.
|Item Type:||Journal Article|
|Subjects:||B Philosophy. Psychology. Religion > BF Psychology
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
|Divisions:||Faculty of Science > WMG (Formerly the Warwick Manufacturing Group)|
|Journal or Publication Title:||Supportive Care In Cancer|
|Number of Pages:||2|
|Access rights to Published version:||Restricted or Subscription Access|
|Version or Related Resource:||This item was originally presented at the 2011 International MASCC/ISOO Symposium, Athens, Greece, Jun 23-25, 2011|
Actions (login required)